Cellular Uptake and Antiproliferative Effects of Therapeutic Concentrations of Idarubicin or Daunorubicin and their Alcohol Metabolites, with or without Cyclosporin A, in MDR1+ Human Leukemic Cells

References

• Richardson D. S., Johnson S. A. Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Rev 1997; 11: 201–223
   PubMed Web of Science ®Google Scholar
• Hannun Y. A. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997; 89: 1845–1853
   PubMed Web of Science ®Google Scholar
• Speth P. A. J., Mindeman H., Haanen C. Idaru‐bicin V daunorubicin: preclinical and clinical pharmacoki‐netic studies. Semin Oncol 1989; 16(Suppl 2)2–9
   PubMedGoogle Scholar
• Reid J. M., Pendergrass T. W., Krailo M. D., Hammond G. D., Ames M. M. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubi‐cinol in pediatric leukemia patients. A Childrens Cancer Study Group report. Cancer Res 1990; 50: 6525–6528
   PubMed Web of Science ®Google Scholar
• Ames M. A., Spreafico F. Selected pharmacologic characteristics of idarubicin and idarubicinol. Leukemia 1992; 6(Suppl 1)70–75
   PubMedGoogle Scholar
• Zanette L., Zucchetti M., Freshi A., Erranti D., Tirelli U., D'lncalci M. Pharmacokinetics of 4‐demethoxy‐daunornbicin in cancer patients. Cancer Chemother Pharmacol 1990; 25: 445–448
   PubMed Web of Science ®Google Scholar
• Johnson S. A., Richardson D. S. Anthracyclines in haematology: pharmacokinetics and clinical studies. Blood Rev 1998; 12: 52–71
   PubMed Web of Science ®Google Scholar
• Muller C., Chateiut E., Gualano V., De Fomi M., Hugnet F., Attal M., Canal P., Laurent G. Cellular pharmacokinetics of doxorubicin in patients with chronic lympho‐cytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother Pharmacol 1993; 32: 379–384
   PubMed Web of Science ®Google Scholar
• Bassan R., Chiodini B., Zucchetti M., Lerede T., Comelli P. E., Cortelazzo S., Barbui T. Short course infu‐sional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results. Haematologica 1998; 83: 27–33
   PubMed Web of Science ®Google Scholar
• Wheatley K. Meta‐analysis of randomized trials of idarubicin (IDAR) or mitozantrone (MITO) versus daunorubicin (DNR) as induction therapy for acute myeloid leukemia (AML) (Abstrat). Blood 1995; 86(Suppl 1)434a
   Google Scholar
• Bassan R., Barbui T. Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age?. Haematologica 1995; 80: 82–90
   PubMedGoogle Scholar
• Bassan R., Lerede T., Rambaldi A., Di Bona E., Rossi G., Pogliani E., Lambertenghi‐Deliliers G., Porcellini A., Fab‐ris P., Barbui T. The role of anthracyclines in adult acute lymphoblastic leukemia. Leukemia 1996; 10(Suppl 2)S58–S61, S58‐S61
   PubMed Web of Science ®Google Scholar
• Germann U. A. P‐glycoprotein‐a mediator of multi‐drug resistance in tumour cells. Eur J Cancer 1996; 32A: 927–944
   PubMed Web of Science ®Google Scholar
• te Boekhorst P. A. W., Lowenberg B., van Kapel J., Nooter K., Sonneveld P. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia 1995; 9: 1025–1031
   PubMed Web of Science ®Google Scholar
• Del Poeta G., Stasi R., Aronica G., Venditti A., Cox M. C., Bruno A., Buccisano F., Masi M., Tribalto M., Ama‐dori S., Papa G. Clinical relevance of P‐glyco‐protein expression in de novo acute myeloid leukemia. Blood 1996; 87: 1997–2004
   PubMed Web of Science ®Google Scholar
• Berman E., McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human mul‐tidrug‐resistant leukemia cells. Blood 1992; 79: 3267–3273
   PubMed Web of Science ®Google Scholar
• Ross D., Tong Y., Comblatt B. Idarubicin (IDA) is less vulnerable to transport‐mediated multidrug resistance (MDR) than its metabolite idarubicinol (IDAol) or daunorubicin (DNR) (Abstract). Blood 1993; 82(Suppl 1)257a, 1015
   Google Scholar
• Kuffel M. J., Reid J. M., Ames M. M. Anthracyclines and their C‐13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 1992; 30: 51–57
   PubMed Web of Science ®Google Scholar
• Michieli M., Michelutti A., Damiani D., Pipan C., Raspa‐don D., Lauria F., Baccarani M. A comparative analyis of sensitivity of multidrug resistant (MDR) and non‐MDR cells to different anthracycline derivatives. Leuk Lymphoma 1993; 9: 255–264
   PubMed Web of Science ®Google Scholar
• List A. F., Speier C., Greer J., Wolff S., Hutter J., Dorr R., Salmon S., Futscher B., Baier B., Dalton W. Phase I/II trial of cyclosporine as a chemotherapy‐resistance modifier in acute leukemia. J Clin Oncol 1993; 11: 1652–1660
   PubMed Web of Science ®Google Scholar
• List A. F. The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 1996; 10(Suppl 2)S46–S51
   Google Scholar
• Hegewisch‐Becker S. MDRI reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Leukemia 1996; 10(Suppl 3)S32–S38
   Google Scholar
• Kornblau S. M., Estey E., Madden T., Tran H. T., Zhao S., Consoli U., Snell V., Sanchez‐Williams G., Kantarjian H., Keating M., Newman R. A., Andreeff M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC‐833 in relapsed or refractory acute myelog‐enous leukemia. J Clin Oncol 1997; 15: 1796–1802
   PubMed Web of Science ®Google Scholar
• Leith C. P., Chen I. ‐M., Kopecky K. J., Appelbaum F. R., Head D. R., Godwin J. E., Weick J. K., Willman C. L. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR/efflux+ and MDR+/efflux− cases. Blood 1995; 86: 2329–2542
   PubMed Web of Science ®Google Scholar
• Bassan R., Chiodini B., Lerede T., Toni V., Rambaldi A., Barbui T. The role of idarubicin in adult acute lymphoblastic leukemia: from drug resistance studies to clinical application. Leukemia Lymphoma 1997; 26(Suppl l)89–97
   PubMed Web of Science ®Google Scholar
• Koopman G., Reutelingsperger C. P. M., Kuijten G. A. M., Keehnen R. M. J., Pals S. T., van Oers M. H. J. Annexin V for flow cytometric detection of phosphati‐dylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415–1420
   PubMed Web of Science ®Google Scholar
• Geyp M., Ireland C. M., Pittman S. M. Resistance to apoptotic cell death in a drug resistant T cell leukemia cell line. Leukemia 1996; 10: 447–455
   PubMed Web of Science ®Google Scholar
• Kokenberg E., Sonneveld P., Delwel R., Sizoo W., Hagen‐heek A., Löwenberg B. In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry. Leukemia 1988; 2: 511–517
   PubMed Web of Science ®Google Scholar
• Pieters R., Loonen A. H., Huismans D. R., Broekema G. J., Dirven M. W. J., Heyenbrok M. W., Hahlen K., Veerman A. J. P. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327–2336
   PubMed Web of Science ®Google Scholar
• Damiani D., Michieli M., Michelutti A., Pea F., Baraldo M., Fanin R., Russo D., Furlanut M., Baccarani M. P170‐related multidrug resistance. Enhancement of idarubicin content in leukemic cells with cyclosporin in vivo: a report of two cases. Leukemia 1995; 9: 1792–1795
   PubMed Web of Science ®Google Scholar
• Grey M. R., Burgess R., Fisher A., Liu Yin J. A. Idarubicin is superior to daunorubicin when used with the multidrug resistance modifier, PSC 833, in acute myeloid leukemia (Abstract). Br J Haematol 1996; 93(Suppl l)245, 64
   Google Scholar
• Minderman H., Linssen P., van der Lely N., Wessels J., Boezeman J., de Witte T., Haanen C. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state. Leukemia 1994; 8: 382–387
   PubMed Web of Science ®Google Scholar
• Ito C., Ribeiro R. C., Behm F. G., Raimondi S. C., Pui C. ‐H., Campana D. Cyclosporine A induces apoptosis in childhood acute lymphoblastic leukemia cells. Blood 1998; 91: 1001–1007
   PubMed Web of Science ®Google Scholar
• Ross D. D., Wooten P. J., Tong Y., Cornblatt B., Levy C., Sridhara R., Lee E. J., Schiffer C. A. Synergis‐tic reversal of multidrug‐resistance phenotype in acute myeloid leukemia by cyclosporin A and cremophor EL. Blood 1994; 83: 1337–1347
   PubMed Web of Science ®Google Scholar